It is the first FDA-approved product for the Cambridge, Massachusetts-based company
Lack of Human Clinical Data The most significant limitation is the near-complete absence of published human clinical trial data: No peer-reviewed human efficacy trials exist in scientific literature as of 2025 One analog compound (CB4211) completed Phase 1 safety testing, but results not published in peer-reviewed journals Human optimal dosing, safety profile, and efficacy completely unestablished Long-term effects of exogenous MOTS-c administration in humans unknown No published data on human absorption, distribution, metabolism, or excretion While endogenous MOTS-c levels have been measured in human populations and exercise studies confirm its physiological presence, therapeutic use remains entirely experimental
Other common side effects include: Dizziness
Gofrit ON, Bercovier H, Klein BY, Cohen IR, Ben-Hur T, Greenblatt CL
Is NAD+ therapy safe for weight loss
Contents are sold by weight, not volume